Health Catalyst, Inc.

Health Catalyst, Inc. reported a significant net loss of $151.6 million for the six months ended June 30, 2026, largely driven by a $122.5 million goodwill impairment charge. Total revenue for the second quarter decreased by 12.7% to $70.5 million compared to the prior year. Despite the losses, the company saw an improvement in net cash provided by operating activities, reaching $18.8 million year-to-date. The balance sheet also reflects $91.4 million in assets held for sale.

Health Catalyst completed the divestiture of its Vitalware business to Med-Metrix, LLC for $147 million on July 31, 2026. The company used the proceeds, along with cash on hand, to fully repay and terminate its credit facility, eliminating approximately $19 million in annual interest expense and sharpening its strategic focus. For Q2 2026, Health Catalyst reported total revenue of $70.487 million, a net loss of $(40.537) million, and Adjusted EBITDA of $9.919 million, exceeding revenue guidance.

Health Catalyst, Inc. announced it will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. Following the release, the company will host a conference call at 5:00 pm ET on the same day to discuss the results. Participants can access the call via dial-in or a live audio webcast.

Health Catalyst, Inc. announced that members of its senior management, including CEO Ben Albert, will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference. Albert is scheduled to join a panel discussion titled "AI ROI in Healthcare: Real vs Hype Debate" on Wednesday, June 24, 2026, at 3:30pm ET. Health Catalyst is a healthcare intelligence company focused on accelerating measurable improvement for health systems.

Health Catalyst, Inc. announced a definitive agreement to divest its Vitalware business unit, a mid-revenue cycle business, to Med-Metrix for $147 million in cash. This divestiture is expected to sharpen Health Catalyst's focus on core technology and AI investments, accelerating its broader transformation. The company plans to use the net proceeds, combined with cash on hand, to fully repay its existing senior secured term loan facility of approximately $160 million.

Health Catalyst, Inc. has filed a Definitive Proxy Statement (DEF 14A) announcing its 2026 Annual Meeting of Stockholders, scheduled to be held virtually on July 16, 2026. The meeting agenda includes the election of two Class I directors, ratification of Ernst & Young LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and a proposal to restate the Amended and Restated Certificate of Incorporation to phase out the classified board structure. The board of directors recommends a vote in favor of all proposals. Stockholders of record as of May 22, 2026, are eligible to vote.

Health Catalyst, Inc. reported a significant net loss of $(111.0) million for the first quarter of 2026, primarily due to a substantial $95.5 million goodwill impairment charge. Total revenue declined to $70.8 million from $79.4 million in the same period last year, with both technology and professional services segments experiencing decreases. Despite the overall financial losses, the company saw a notable increase in net cash provided by operating activities.

Health Catalyst reported a Q1 2026 net loss of $(111.0) million, a 368% increase from the prior year, primarily due to a $95.5 million goodwill impairment. Total revenue decreased by 11% to $70.8 million, while Adjusted EBITDA increased by 46% to $9.1 million, exceeding expectations. The company announced a strategic reset to transform its operating model and provided Q2 2026 revenue guidance of $68-$70 million and full-year guidance of $260-$265 million.

Health Catalyst, Inc. announced it will release its first quarter 2026 operating results on Monday, May 11, 2026, after market close. The company will host a conference call to discuss these results on the same day at 5:00 pm ET. Participants can join by dialing 800-343-5172 (U.S.) or 203-518-9856 (International) using conference ID "HCATQ126," or via a live audio webcast on the company's investor relations website.

Health Catalyst, Inc. filed an Amendment No. 1 to its 2024 Form 10-K to include detailed information on directors, executive officers, corporate governance, executive compensation, and related matters. The company announced significant leadership changes, including the appointment of Benjamin Albert as CEO, the retirement of Daniel Burton, and the departures of other key executives. The Board also saw new appointments and a non-renomination. The filing also outlined updates to the executive compensation program for fiscal years 2025 and 2026, including a shift in the 2026 bonus plan to 100% cash.